0.1949

12.53% 0.0217

After Hours: .19 -0.0049 -2.51%

Gossamer Bio Inc (GOSS)

Overview News Price History Option Chain Financials Discussions Forecast

Gossamer Bio Inc stock is traded at $0.1949, with a volume of 16.46M. It is up +12.53% in the last 24 hours and up +11.37% over the past month. Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).

Previous Close:

$0.1732

Open:

$0.1732

24h Volume:

16.46M

Relative Volume:

1.41

Market Cap:

$95.28M

Revenue:

$55.54M

Net Income/Loss:

$-180.40M

P/E Ratio:

-0.2474

EPS:

-0.7877

Net Cash Flow:

$-170.32M

1W Performance:

+18.84%

1M Performance:

+11.37%

6M Performance:

-92.39%

1Y Performance:

-84.28%

1-Day Range:

$0.1655

$0.1949

1-Week Range:

$0.1622

$0.1949

52-Week Range:

$0.14

$3.87

Gossamer Bio Inc Stock (GOSS) Company Profile

Name

Gossamer Bio Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

(858) 684-1300

Address

3115 MERRYFIELD ROW, SAN DIEGO, CA

Employee

162

Twitter

@GossamerBio

Next Earnings Date

2026-08-04

Latest SEC Filings

GOSS's Discussions on Twitter

Compare GOSS vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GOSS Gossamer Bio Inc	0.1949	80.46M	55.54M	-180.40M	-170.32M	-0.7877
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-23-26	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-24-26	Downgrade	Barclays	Overweight → Equal Weight
Feb-24-26	Downgrade	Leerink Partners	Outperform → Market Perform
Feb-24-26	Downgrade	Wedbush	Outperform → Neutral
Jan-28-26	Initiated	Barclays	Overweight
Sep-10-25	Upgrade	UBS	Neutral → Buy
Jul-14-25	Initiated	Scotiabank	Sector Outperform
Jun-25-24	Initiated	Oppenheimer	Outperform
Apr-05-24	Resumed	Wedbush	Outperform
Jul-27-23	Downgrade	UBS	Buy → Neutral
Mar-07-23	Downgrade	Raymond James	Outperform → Mkt Perform
Mar-01-23	Initiated	Guggenheim	Neutral
Dec-07-22	Downgrade	Barclays	Overweight → Equal Weight
Dec-07-22	Downgrade	JP Morgan	Neutral → Underweight
Dec-07-22	Downgrade	SMBC Nikko	Outperform → Neutral
Oct-20-22	Initiated	Goldman	Buy
Sep-21-22	Initiated	JP Morgan	Neutral
Sep-19-22	Initiated	Wedbush	Outperform
Apr-18-22	Initiated	Raymond James	Outperform
Apr-06-22	Initiated	UBS	Buy
Jan-10-22	Upgrade	SMBC Nikko	Neutral → Outperform
Nov-09-21	Resumed	Cantor Fitzgerald	Overweight
Sep-21-21	Resumed	Piper Sandler	Overweight
Jun-29-20	Initiated	H.C. Wainwright	Buy
Apr-22-20	Initiated	Piper Sandler	Overweight
Feb-27-20	Initiated	Barclays	Overweight
Dec-03-19	Resumed	BofA/Merrill	Buy
Oct-30-19	Initiated	Berenberg	Buy
Mar-05-19	Initiated	Barclays	Overweight
Mar-05-19	Initiated	BofA/Merrill	Buy
Mar-05-19	Initiated	Evercore ISI	Outperform
Mar-05-19	Initiated	SVB Leerink	Outperform

View All

Gossamer Bio Inc Stock (GOSS) Latest News

Jul 01, 2026

D.E. Shaw discloses 8.3% Gossamer Bio (GOSS) ownership stake - Stock Titan

Jul 01, 2026

Form 13D/A Gossamer Bio For: 1 July By Investing.com - Investing.com Canada

Jul 01, 2026

GOSS: Gossamer Bio Sets Initial Conversion Rate for Convertible Notes - GuruFocus

Jul 01, 2026

Gossamer Bio sets conversion rate for 2030 convertible notes By Investing.com - Investing.com Nigeria

Jul 01, 2026

Gossamer Bio sets conversion rate for 2030 convertible notes - Investing.com

Jul 01, 2026

Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants - marketscreener.com

Jul 01, 2026

Gossamer Bio (NASDAQ: GOSS) sets note conversion rate and warrant exercise price - Stock Titan

Jul 01, 2026

Jun 30, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Gossamer Bio, Inc - The National Law Review

Jun 30, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review

Jun 30, 2026

Jun 29, 2026

Enterprise value to revenue forward of Gossamer Bio, Inc. – SWB:4GB - TradingView

Jun 29, 2026

Price to earnings forward of Gossamer Bio, Inc. – SWB:4GB - TradingView

Jun 29, 2026

Jun 26, 2026

H.C. Wainwright cuts Gossamer Bio stock price target to $2 on debt exchange By Investing.com - Investing.com Australia

Jun 26, 2026